{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:48:15Z","timestamp":1785422895648,"version":"3.56.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007298","name":"Urmia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007298","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Among the DNA-damaging agents commonly used in clinical settings doxorubicin has emerged as one of the most effective treatments for Triple-negative breast cancer (TNBC). Our limited understanding about the molecular mechanisms underlying the short- and long-term responses of TNBC cells to DNA damage induced by drugs like doxorubicin is a hurdle to improve the efficacy of the treatment or overcome the drug resistance. In this study, we aimed to elucidate the immediate response of the TNBC cells to doxorubicin and compare these responses with those of doxorubicin-resistant cells through transcriptome analysis. Transcriptome analysis revealed that doxorubicin significantly upregulates the expression of TP53 target genes, including\n                    <jats:italic>CDKN1A<\/jats:italic>\n                    ,\n                    <jats:italic>TIGAR<\/jats:italic>\n                    ,\n                    <jats:italic>TP53INP1<\/jats:italic>\n                    ,\n                    <jats:italic>PPM1D<\/jats:italic>\n                    , and\n                    <jats:italic>ACER2<\/jats:italic>\n                    . Notably, doxorubicin-resistant TNBC cells failed to increase the expression of these genes, except for\n                    <jats:italic>CDKN1A<\/jats:italic>\n                    , upon doxorubicin treatment. Moreover, treatment with etoposide as another DNA-damaging drug increased the expression of\n                    <jats:italic>CDKN1A<\/jats:italic>\n                    ,\n                    <jats:italic>TP53INP1<\/jats:italic>\n                    , and\n                    <jats:italic>ACER2<\/jats:italic>\n                    in a TP53-independent manner. Collectively, this study highlights the critical role of TP53 target genes in the immediate response of TNBC cells to DNA-damaging agents like doxorubicin and etoposide. It also reveals distinct molecular mechanisms regulating their expression in resistant versus sensitive cells, offering potential therapeutic targets to improve treatment strategies for TNBC.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-31087-x","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:14:38Z","timestamp":1764854078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Activation of TP53 target genes in the primary response of triple-negative breast cancer cells to doxorubicin treatment"],"prefix":"10.1038","volume":"16","author":[{"given":"Aysan","family":"Shekari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaghub","family":"Pazhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Maadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"31087_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.soc.2017.08.005","volume":"27","author":"SM Fragomeni","year":"2018","unstructured":"Fragomeni, S. M., Sciallis, A. & Jeruss, J. S. Molecular subtypes and Local-Regional control of breast cancer. Surg. Oncol. Clin. N Am. 27, 95\u2013120. https:\/\/doi.org\/10.1016\/j.soc.2017.08.005 (2018).","journal-title":"Surg. Oncol. Clin. N Am."},{"key":"31087_CR2","doi-asserted-by":"publisher","first-page":"e18761429263841","DOI":"10.2174\/0118761429263841230926014118","volume":"17","author":"Y Naeimzadeh","year":"2024","unstructured":"Naeimzadeh, Y., Heidari, Z., Razban, V. & Khajeh, S. Deregulated MicroRNAs involved in P53 signaling pathway in breast cancer with focus on Triple-negative breast cancer. Curr. Mol. Pharmacol. 17, e18761429263841. https:\/\/doi.org\/10.2174\/0118761429263841230926014118 (2024).","journal-title":"Curr. Mol. Pharmacol."},{"key":"31087_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbagen.2016.11.013","volume":"1861","author":"S Aydinlik","year":"2017","unstructured":"Aydinlik, S. et al. Enhanced cytotoxic activity of doxorubicin through the Inhibition of autophagy in triple negative breast cancer cell line. Biochim. Biophys. Acta Gen. Subj. 1861, 49\u201357. https:\/\/doi.org\/10.1016\/j.bbagen.2016.11.013 (2017).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"31087_CR4","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/jci45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750\u20132767. https:\/\/doi.org\/10.1172\/jci45014 (2011).","journal-title":"J. Clin. Invest."},{"key":"31087_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674\u2013690. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"31087_CR6","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1007\/s00432-022-04189-6","volume":"149","author":"A Mandapati","year":"2023","unstructured":"Mandapati, A. & Lukong, K. E. Triple negative breast cancer: approved treatment options and their mechanisms of action. J. Cancer Res. Clin. Oncol. 149, 3701\u20133719. https:\/\/doi.org\/10.1007\/s00432-022-04189-6 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"31087_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113480","author":"J Marinello","year":"2018","unstructured":"Marinello, J., Delcuratolo, M. & Capranico, G. Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms19113480 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"31087_CR8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrm.2016.111","volume":"17","author":"Y Pommier","year":"2016","unstructured":"Pommier, Y., Sun, Y., Huang, S. N. & Nitiss, J. L. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat. Rev. Mol. Cell. Biol. 17, 703\u2013721. https:\/\/doi.org\/10.1038\/nrm.2016.111 (2016).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"31087_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","volume":"7","author":"H Cort\u00e9s-Funes","year":"2007","unstructured":"Cort\u00e9s-Funes, H. & Coronado, C. Role of anthracyclines in the era of targeted therapy. Cardiovasc. Toxicol. 7, 56\u201360. https:\/\/doi.org\/10.1007\/s12012-007-0015-3 (2007).","journal-title":"Cardiovasc. Toxicol."},{"key":"31087_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells12040659","author":"M Kciuk","year":"2023","unstructured":"Kciuk, M. et al. Doxorubicin-an agent with multiple mechanisms of anticancer activity. Cells https:\/\/doi.org\/10.3390\/cells12040659(2023).","journal-title":"Cells"},{"key":"31087_CR11","unstructured":"Micallef, I., Baron, B. & Doxorubicin An overview of the anti-cancer and chemoresistance mechanisms. (2020)."},{"key":"31087_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092392","author":"GK Gupta","year":"2020","unstructured":"Gupta, G. K. et al. Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12092392 (2020).","journal-title":"Cancers (Basel)"},{"key":"31087_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071796","author":"O Obidiro","year":"2023","unstructured":"Obidiro, O., Battogtokh, G. & Akala, E. O. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics15071796 (2023).","journal-title":"Pharmaceutics"},{"key":"31087_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/1874467215666220329212300","volume":"16","author":"Y Cai","year":"2023","unstructured":"Cai, Y., Sheng, Z., Dong, Z., Wang, J. E. G. F. R. & Inhibitor CL-387785 suppresses the progression of lung adenocarcinoma. Curr. Mol. Pharmacol. 16, 211\u2013216. https:\/\/doi.org\/10.2174\/1874467215666220329212300 (2023).","journal-title":"Curr. Mol. Pharmacol."},{"key":"31087_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/s41419-021-04405-0","volume":"12","author":"D Mehlich","year":"2021","unstructured":"Mehlich, D. et al. MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. Cell. Death Dis. 12, 1111. https:\/\/doi.org\/10.1038\/s41419-021-04405-0 (2021).","journal-title":"Cell. Death Dis."},{"key":"31087_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.Cd-23-0402","volume":"14","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Loss-of-Function but not Gain-of-Function properties of mutant TP53 are critical for the Proliferation, Survival, and metastasis of a broad range of cancer cells. Cancer Discov. 14, 362\u2013379. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0402 (2024).","journal-title":"Cancer Discov"},{"key":"31087_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527. https:\/\/doi.org\/10.1038\/nbt.3519 (2016).","journal-title":"Nat. Biotechnol."},{"key":"31087_CR18","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.2","volume":"4","author":"C Soneson","year":"2015","unstructured":"Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4, 1521. https:\/\/doi.org\/10.12688\/f1000research.7563.2 (2015).","journal-title":"F1000Res"},{"key":"31087_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. EdgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140. https:\/\/doi.org\/10.1093\/bioinformatics\/btp616 (2010).","journal-title":"Bioinformatics"},{"key":"31087_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0169-7439(87)80084-9","volume":"2","author":"S Wold","year":"1987","unstructured":"Wold, S., Esbensen, K. & Geladi, P. Principal component analysis. Chemometr. Intell. Lab. Syst. 2, 37\u201352. https:\/\/doi.org\/10.1016\/0169-7439(87)80084-9 (1987).","journal-title":"Chemometr. Intell. Lab. Syst."},{"key":"31087_CR21","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47\u2013e47. https:\/\/doi.org\/10.1093\/nar\/gkv007 (2015).","journal-title":"Nucleic Acids Res."},{"key":"31087_CR22","unstructured":"Warnes, G. et al. T. gplots: Various R Programming Tools for Plotting Data, < https:\/\/github.com\/talgalili\/gplots(2024)."},{"key":"31087_CR23","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer-, 2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"31087_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2105-12-35","volume":"12","author":"H Chen","year":"2011","unstructured":"Chen, H. & Boutros, P. C. VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinform. 12, 35. https:\/\/doi.org\/10.1186\/1471-2105-12-35 (2011).","journal-title":"BMC Bioinform."},{"key":"31087_CR25","doi-asserted-by":"publisher","first-page":"146930","DOI":"10.1016\/j.gene.2022.146930","volume":"850","author":"U Kumar","year":"2023","unstructured":"Kumar, U., Castellanos-Uribe, M., May, S. T. & Yag\u00fce, E. Adaptive resistance is not responsible for long-term drug resistance in a cellular model of triple negative breast cancer. Gene 850, 146930. https:\/\/doi.org\/10.1016\/j.gene.2022.146930 (2023).","journal-title":"Gene"},{"key":"31087_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy\u2014analysis of affymetrix genechip data at the probe level. Bioinformatics 20, 307\u2013315. https:\/\/doi.org\/10.1093\/bioinformatics\/btg405 (2004).","journal-title":"Bioinformatics"},{"key":"31087_CR27","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961. https:\/\/doi.org\/10.1093\/nar\/gks1111 (2013).","journal-title":"Nucleic Acids Res."},{"key":"31087_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.Cd-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404. https:\/\/doi.org\/10.1158\/2159-8290.Cd-12-0095 (2012).","journal-title":"Cancer Discov"},{"key":"31087_CR29","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088 (2013).","journal-title":"Sci. Signal."},{"key":"31087_CR30","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.Can-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn, I. et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal. Cancer Res. 83, 3861\u20133867. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-0816 (2023).","journal-title":"Cancer Res."},{"key":"31087_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi, M. et al. Next-generation characterization of the cancer cell line encyclopedia. Nature 569, 503\u2013508. https:\/\/doi.org\/10.1038\/s41586-019-1186-3 (2019).","journal-title":"Nature"},{"key":"31087_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","volume":"180","author":"DP Nusinow","year":"2020","unstructured":"Nusinow, D. P. et al. Quantitative proteomics of the cancer cell line encyclopedia. Cell 180, 387\u2013402e316. https:\/\/doi.org\/10.1016\/j.cell.2019.12.023 (2020).","journal-title":"Cell"},{"key":"31087_CR33","doi-asserted-by":"publisher","first-page":"11479","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat. Commun. 7, 11479. https:\/\/doi.org\/10.1038\/ncomms11479 (2016).","journal-title":"Nat. Commun."},{"key":"31087_CR34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1007-8","volume":"567","author":"OM Rueda","year":"2019","unstructured":"Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature 567, 399\u2013404. https:\/\/doi.org\/10.1038\/s41586-019-1007-8 (2019).","journal-title":"Nature"},{"key":"31087_CR35","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352. https:\/\/doi.org\/10.1038\/nature10983 (2012).","journal-title":"Nature"},{"key":"31087_CR36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi, P. et al. The genomic landscape of Endocrine-Resistant advanced breast cancers. Cancer Cell. 34, 427\u2013438e426. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.008 (2018).","journal-title":"Cancer Cell."},{"key":"31087_CR37","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41467-018-04129-4","volume":"9","author":"Z Kan","year":"2018","unstructured":"Kan, Z. et al. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nat. Commun. 9, 1725. https:\/\/doi.org\/10.1038\/s41467-018-04129-4 (2018).","journal-title":"Nat. Commun."},{"key":"31087_CR38","doi-asserted-by":"publisher","first-page":"e1002201","DOI":"10.1371\/journal.pmed.1002201","volume":"13","author":"C Lefebvre","year":"2016","unstructured":"Lefebvre, C. et al. Mutational profile of metastatic breast cancers: A retrospective analysis. PLoS Med. 13, e1002201. https:\/\/doi.org\/10.1371\/journal.pmed.1002201 (2016).","journal-title":"PLoS Med."},{"key":"31087_CR39","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013W560. https:\/\/doi.org\/10.1093\/nar\/gkz430 (2019).","journal-title":"Nucleic Acids Res."},{"key":"31087_CR40","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk, D. et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638\u2013d646. https:\/\/doi.org\/10.1093\/nar\/gkac1000 (2023).","journal-title":"Nucleic Acids Res."},{"key":"31087_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C. & Vazquez, F. The present and future of the cancer dependency map. Nat. Rev. Cancer. 25, 59\u201373. https:\/\/doi.org\/10.1038\/s41568-024-00763-x (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"31087_CR42","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand, U. et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 10, 1367\u20131401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007 (2023).","journal-title":"Genes Dis."},{"key":"31087_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/mol.119.117259","volume":"96","author":"M Atwal","year":"2019","unstructured":"Atwal, M. et al. Intercalating TOP2 poisons attenuate topoisomerase action at higher concentrations. Mol. Pharmacol. 96, 475\u2013484. https:\/\/doi.org\/10.1124\/mol.119.117259 (2019).","journal-title":"Mol. Pharmacol."},{"key":"31087_CR44","unstructured":"The TP53 Database (R21. : Aug (2024). https:\/\/tp53.cancer.gov"},{"key":"31087_CR45","doi-asserted-by":"publisher","first-page":"44573","DOI":"10.1038\/srep44573","volume":"7","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. Alkaline ceramidase 2 is a novel direct target of p53 and induces autophagy and apoptosis through ROS generation. Sci. Rep. 7, 44573. https:\/\/doi.org\/10.1038\/srep44573 (2017).","journal-title":"Sci. Rep."},{"key":"31087_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.17179\/excli2015-561","volume":"14","author":"A Montecucco","year":"2015","unstructured":"Montecucco, A., Zanetta, F. & Biamonti, G. Molecular mechanisms of Etoposide. Excli j. 14, 95\u2013108. https:\/\/doi.org\/10.17179\/excli2015-561 (2015).","journal-title":"Excli j."},{"key":"31087_CR47","doi-asserted-by":"publisher","first-page":"101205","DOI":"10.1016\/j.mam.2023.101205","volume":"93","author":"R Mattioli","year":"2023","unstructured":"Mattioli, R. et al. Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming. Mol. Aspects Med. 93, 101205. https:\/\/doi.org\/10.1016\/j.mam.2023.101205 (2023).","journal-title":"Mol. Aspects Med."},{"key":"31087_CR48","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc2607","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss, J. L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer. 9, 338\u2013350. https:\/\/doi.org\/10.1038\/nrc2607 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"31087_CR49","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1039\/c8cp06776g","volume":"21","author":"B Jawad","year":"2019","unstructured":"Jawad, B., Poudel, L., Podgornik, R., Steinmetz, N. F. & Ching, W. Y. Molecular mechanism and binding free energy of doxorubicin intercalation in DNA. Phys. Chem. Chem. Phys. 21, 3877\u20133893. https:\/\/doi.org\/10.1039\/c8cp06776g (2019).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"31087_CR50","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.bbrc.2009.08.085","volume":"388","author":"M Gilleron","year":"2009","unstructured":"Gilleron, M. et al. NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem. Biophys. Res. Commun. 388, 727\u2013731. https:\/\/doi.org\/10.1016\/j.bbrc.2009.08.085 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"31087_CR51","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/emm.2006.63","volume":"38","author":"SY Kim","year":"2006","unstructured":"Kim, S. Y. et al. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2\u2009+\u2009increase are reciprocally modulated in rat cardiomyocytes. Exp. Mol. Med. 38, 535\u2013545. https:\/\/doi.org\/10.1038\/emm.2006.63 (2006).","journal-title":"Exp. Mol. Med."},{"key":"31087_CR52","doi-asserted-by":"publisher","first-page":"C195","DOI":"10.1152\/ajpcell.00217.2011","volume":"302","author":"LA Gilliam","year":"2012","unstructured":"Gilliam, L. A. et al. Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes. Am. J. Physiol. Cell. Physiol. 302, C195\u2013202. https:\/\/doi.org\/10.1152\/ajpcell.00217.2011 (2012).","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"31087_CR53","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0024-3205(03)00566-6","volume":"73","author":"WP Tsang","year":"2003","unstructured":"Tsang, W. P., Chau, S. P. Y., Kong, S. K., Fung, K. P. & Kwok, T. T. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci. 73, 2047\u20132058. https:\/\/doi.org\/10.1016\/S0024-3205(03)00566-6 (2003).","journal-title":"Life Sci."},{"key":"31087_CR54","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.4161\/cc.9.9.11483","volume":"9","author":"SL Abrams","year":"2010","unstructured":"Abrams, S. L. et al. The Raf\/MEK\/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell. Cycle. 9, 1781\u20131791. https:\/\/doi.org\/10.4161\/cc.9.9.11483 (2010).","journal-title":"Cell. Cycle"},{"key":"31087_CR55","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1186\/s12885-019-5939-z","volume":"19","author":"C Christowitz","year":"2019","unstructured":"Christowitz, C. et al. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer. 19, 757. https:\/\/doi.org\/10.1186\/s12885-019-5939-z (2019).","journal-title":"BMC Cancer"},{"key":"31087_CR56","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1002\/jcb.26107","volume":"118","author":"Y Li","year":"2017","unstructured":"Li, Y., Ye, Y., Feng, B. & Qi, Y. Long noncoding RNA LncARSR promotes doxorubicin resistance in hepatocellular carcinoma via modulating PTEN-PI3K\/Akt pathway. J. Cell. Biochem. 118, 4498\u20134507. https:\/\/doi.org\/10.1002\/jcb.26107 (2017).","journal-title":"J. Cell. Biochem."},{"key":"31087_CR57","doi-asserted-by":"publisher","first-page":"610","DOI":"10.18632\/oncotarget.315","volume":"2","author":"JR Taylor","year":"2011","unstructured":"Taylor, J. R. et al. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or Tamoxifen treated breast cancer cells. Oncotarget 2, 610\u2013626. https:\/\/doi.org\/10.18632\/oncotarget.315 (2011).","journal-title":"Oncotarget"},{"key":"31087_CR58","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.neo.2019.09.002","volume":"21","author":"CD Stefanski","year":"2019","unstructured":"Stefanski, C. D., Keffler, K., McClintock, S., Milac, L. & Prosperi, J. R. APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells. Neoplasia 21, 1143\u20131150. https:\/\/doi.org\/10.1016\/j.neo.2019.09.002 (2019).","journal-title":"Neoplasia"},{"key":"31087_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071770","author":"UK Hussein","year":"2021","unstructured":"Hussein, U. K. et al. CK2\u03b1\/CSNK2A1 induces resistance to doxorubicin through SIRT6-mediated activation of the DNA damage repair pathway. Cells https:\/\/doi.org\/10.3390\/cells10071770 (2021).","journal-title":"Cells"},{"key":"31087_CR60","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/1471-2407-7-203","volume":"7","author":"B Keam","year":"2007","unstructured":"Keam, B. et al. Prognostic impact of clinicopathologic parameters in stage II\/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: Paradoxical features of the triple negative breast cancer. BMC Cancer. 7, 203. https:\/\/doi.org\/10.1186\/1471-2407-7-203 (2007).","journal-title":"BMC Cancer"},{"key":"31087_CR61","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.molcel.2006.05.015","volume":"22","author":"M Kitayner","year":"2006","unstructured":"Kitayner, M. et al. Structural basis of DNA recognition by p53 tetramers. Mol. Cell. 22, 741\u2013753. https:\/\/doi.org\/10.1016\/j.molcel.2006.05.015 (2006).","journal-title":"Mol. Cell."},{"key":"31087_CR62","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/ijms19041184","volume":"19","author":"AS Gomes","year":"2018","unstructured":"Gomes, A. S. et al. The crystal structure of the R280K mutant of human p53 explains the loss of DNA binding. Int. J. Mol. Sci. 19, 1184 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"31087_CR63","doi-asserted-by":"publisher","first-page":"ijerph13010022","DOI":"10.3390\/ijerph13010022","volume":"13","author":"N Shtraizent","year":"2015","unstructured":"Shtraizent, N., Matsui, H., Polotskaia, A. & Bargonetti, J. Hot spot mutation in TP53 (R248Q) causes oncogenic Gain-of-Function phenotypes in a breast cancer cell line derived from an African American patient. Int. J. Environ. Res. Public. Health. 13, ijerph13010022. https:\/\/doi.org\/10.3390\/ijerph13010022 (2015).","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"31087_CR64","first-page":"1169","volume":"54","author":"WS el-Deiry","year":"1994","unstructured":"el-Deiry, W. S. et al. WAF1\/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54, 1169\u20131174 (1994).","journal-title":"Cancer Res."},{"key":"31087_CR65","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0092-8674(93)90500-p","volume":"75","author":"WS el-Deiry","year":"1993","unstructured":"el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817\u2013825. https:\/\/doi.org\/10.1016\/0092-8674(93)90500-p (1993).","journal-title":"Cell"},{"key":"31087_CR66","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1097-2765(01)00284-2","volume":"8","author":"S Okamura","year":"2001","unstructured":"Okamura, S. et al. p53DINP1, a p53-Inducible Gene, regulates p53-Dependent apoptosis. Mol. Cell. 8, 85\u201394. https:\/\/doi.org\/10.1016\/S1097-2765(01)00284-2 (2001).","journal-title":"Mol. Cell"},{"key":"31087_CR67","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1078\/0171-9335-00248","volume":"81","author":"R Tomasini","year":"2002","unstructured":"Tomasini, R. et al. P53-dependent expression of the stress-induced protein (SIP). Eur. J. Cell. Biol. 81, 294\u2013301. https:\/\/doi.org\/10.1078\/0171-9335-00248 (2002).","journal-title":"Eur. J. Cell. Biol."},{"key":"31087_CR68","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1080\/10715762.2018.1489133","volume":"52","author":"J Geng","year":"2018","unstructured":"Geng, J., Yuan, X., Wei, M., Wu, J. & Qin, Z. H. The diverse role of TIGAR in cellular homeostasis and cancer. Free Radic Res. 52, 1240\u20131249. https:\/\/doi.org\/10.1080\/10715762.2018.1489133 (2018).","journal-title":"Free Radic Res."},{"key":"31087_CR69","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cell.2006.05.036","volume":"126","author":"K Bensaad","year":"2006","unstructured":"Bensaad, K. et al. TIGAR, a p53-inducible regulator of Glycolysis and apoptosis. Cell 126, 107\u2013120. https:\/\/doi.org\/10.1016\/j.cell.2006.05.036 (2006).","journal-title":"Cell"},{"key":"31087_CR70","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/bjc.2017.433","volume":"118","author":"CE Wu","year":"2018","unstructured":"Wu, C. E. et al. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. Br. J. Cancer. 118, 495\u2013508. https:\/\/doi.org\/10.1038\/bjc.2017.433 (2018).","journal-title":"Br. J. Cancer"},{"key":"31087_CR71","doi-asserted-by":"publisher","first-page":"8093","DOI":"10.1038\/sj.onc.1208951","volume":"24","author":"R Tomasini","year":"2005","unstructured":"Tomasini, R. et al. TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene 24, 8093\u20138104. https:\/\/doi.org\/10.1038\/sj.onc.1208951 (2005).","journal-title":"Oncogene"},{"key":"31087_CR72","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/sj.cdd.4401575","volume":"12","author":"T Hershko","year":"2005","unstructured":"Hershko, T., Chaussepied, M., Oren, M. & Ginsberg, D. Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell. Death Differ. 12, 377\u2013383. https:\/\/doi.org\/10.1038\/sj.cdd.4401575 (2005).","journal-title":"Cell. Death Differ."},{"key":"31087_CR73","doi-asserted-by":"publisher","first-page":"eabe3882","DOI":"10.1126\/sciadv.abe3882","volume":"7","author":"JF Nathans","year":"2021","unstructured":"Nathans, J. F., Cornwell, J. A., Afifi, M. M., Paul, D. & Cappell, S. D. Cell cycle inertia underlies a bifurcation in cell fates after DNA damage. Sci. Adv. 7, eabe3882. https:\/\/doi.org\/10.1126\/sciadv.abe3882 (2021).","journal-title":"Sci. Adv."},{"key":"31087_CR74","doi-asserted-by":"publisher","first-page":"14728","DOI":"10.1038\/ncomms14728","volume":"8","author":"AR Barr","year":"2017","unstructured":"Barr, A. R. et al. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nat. Commun. 8, 14728. https:\/\/doi.org\/10.1038\/ncomms14728 (2017).","journal-title":"Nat. Commun."},{"key":"31087_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417488","author":"E Manousakis","year":"2023","unstructured":"Manousakis, E., Miralles, C. M., Esquerda, M. G. & Wright, R. H. G. CDKN1A\/p21 in breast cancer: part of the problem, or part of the solution?. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms242417488 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"31087_CR76","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.celrep.2019.03.031","volume":"27","author":"C Sheng","year":"2019","unstructured":"Sheng, C. et al. PCNA-Mediated degradation of p21 coordinates the DNA damage response and cell cycle regulation in individual cells. Cell. Rep. 27, 48\u201358e47. https:\/\/doi.org\/10.1016\/j.celrep.2019.03.031 (2019).","journal-title":"Cell. Rep."},{"key":"31087_CR77","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.bbamcr.2008.01.008","volume":"1783","author":"S Ma","year":"2008","unstructured":"Ma, S. et al. Induction of p21 by p65 in p53 null cells treated with doxorubicin. Biochim. Et Biophys. Acta (BBA) - Mol. Cell. Res. 1783, 935\u2013940. https:\/\/doi.org\/10.1016\/j.bbamcr.2008.01.008 (2008).","journal-title":"Biochim. Et Biophys. Acta (BBA) - Mol. Cell. Res."},{"key":"31087_CR78","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11010-006-9206-7","volume":"291","author":"JJ Tang","year":"2006","unstructured":"Tang, J. J., Shen, C. & Lu, Y. J. Requirement for pre-existing of p21 to prevent doxorubicin-induced apoptosis through Inhibition of caspase-3 activation. Mol. Cell. Biochem. 291, 139\u2013144. https:\/\/doi.org\/10.1007\/s11010-006-9206-7 (2006).","journal-title":"Mol. Cell. Biochem."},{"key":"31087_CR79","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/cdd.2012.30","volume":"19","author":"M Seillier","year":"2012","unstructured":"Seillier, M. et al. TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death. Cell. Death Differ. 19, 1525\u20131535. https:\/\/doi.org\/10.1038\/cdd.2012.30 (2012).","journal-title":"Cell. Death Differ."},{"key":"31087_CR80","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biochi.2015.07.024","volume":"118","author":"H Saadi","year":"2015","unstructured":"Saadi, H., Seillier, M. & Carrier, A. The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasis. Biochimie 118, 44\u201350. https:\/\/doi.org\/10.1016\/j.biochi.2015.07.024 (2015).","journal-title":"Biochimie"},{"key":"31087_CR81","doi-asserted-by":"publisher","first-page":"25450","DOI":"10.3390\/ijms161025450","volume":"16","author":"N S\u00e1ndor","year":"2015","unstructured":"S\u00e1ndor, N. et al. TP53inp1 gene is implicated in early radiation response in human fibroblast cells. Int. J. Mol. Sci. 16, 25450\u201325465. https:\/\/doi.org\/10.3390\/ijms161025450 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"31087_CR82","doi-asserted-by":"publisher","first-page":"1511283","DOI":"10.3389\/fimmu.2024.1511283","volume":"15","author":"B Liu","year":"2024","unstructured":"Liu, B. et al. The role of ACER2 in intestinal sphingolipid metabolism and Gastrointestinal cancers. Front. Immunol. 15, 1511283. https:\/\/doi.org\/10.3389\/fimmu.2024.1511283 (2024).","journal-title":"Front. Immunol."},{"key":"31087_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-017-0018-y","author":"R Xu","year":"2017","unstructured":"Xu, R. et al. Tumor suppressor p53 links ceramide metabolism to DNA damage response through alkaline ceramidase 2. Cell. Death Differ. https:\/\/doi.org\/10.1038\/s41418-017-0018-y (2017).","journal-title":"Cell. Death Differ."},{"key":"31087_CR84","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41419-020-03106-4","volume":"11","author":"S Zhang","year":"2020","unstructured":"Zhang, S. et al. TIMELESS regulates sphingolipid metabolism and tumor cell growth through Sp1\/ACER2\/S1P axis in ER-positive breast cancer. Cell. Death Dis. 11, 892. https:\/\/doi.org\/10.1038\/s41419-020-03106-4 (2020).","journal-title":"Cell. Death Dis."},{"key":"31087_CR85","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1111\/cas.14453","volume":"111","author":"B Liu","year":"2020","unstructured":"Liu, B., Xiao, J., Dong, M., Qiu, Z. & Jin, J. Human alkaline ceramidase 2 promotes the growth, invasion, and migration of hepatocellular carcinoma cells via sphingomyelin phosphodiesterase acid-like 3B. Cancer Sci. 111, 2259\u20132274. https:\/\/doi.org\/10.1111\/cas.14453 (2020).","journal-title":"Cancer Sci."},{"key":"31087_CR86","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1158\/0008-5472.Can-13-3517","volume":"74","author":"JM Xie","year":"2014","unstructured":"Xie, J. M. et al. TIGAR has a dual role in cancer cell survival through regulating apoptosis and autophagy. Cancer Res. 74, 5127\u20135138. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-3517 (2014).","journal-title":"Cancer Res."},{"key":"31087_CR87","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3892\/ol.2019.10574","volume":"18","author":"Z Tang","year":"2019","unstructured":"Tang, Z. & He, Z. TIGAR promotes growth, survival and metastasis through oxidation resistance and AKT activation in glioblastoma. Oncol. Lett. 18, 2509\u20132517. https:\/\/doi.org\/10.3892\/ol.2019.10574 (2019).","journal-title":"Oncol. Lett."},{"key":"31087_CR88","doi-asserted-by":"publisher","first-page":"26291","DOI":"10.1074\/jbc.M116.740209","volume":"291","author":"YH Ko","year":"2016","unstructured":"Ko, Y. H. et al. TP53-inducible Glycolysis and apoptosis regulator (TIGAR) metabolically reprograms carcinoma and stromal cells in breast cancer. J. Biol. Chem. 291, 26291\u201326303. https:\/\/doi.org\/10.1074\/jbc.M116.740209 (2016).","journal-title":"J. Biol. Chem."},{"key":"31087_CR89","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/366701a0","volume":"366","author":"Y Xiong","year":"1993","unstructured":"Xiong, Y. et al. p21 is a universal inhibitor of Cyclin kinases. Nature 366, 701\u2013704. https:\/\/doi.org\/10.1038\/366701a0 (1993).","journal-title":"Nature"},{"key":"31087_CR90","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/0092-8674(93)90499-G","volume":"75","author":"J Wade Harper","year":"1993","unstructured":"Wade Harper, J., Adami, G. R., Wei, N., Keyomarsi, K. & Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805\u2013816. https:\/\/doi.org\/10.1016\/0092-8674(93)90499-G (1993).","journal-title":"Cell"},{"key":"31087_CR91","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11010-013-1696-5","volume":"382","author":"M Askari","year":"2013","unstructured":"Askari, M., Sobti, R. C., Nikbakht, M. & Sharma, S. C. Aberrant promoter hypermethylation of p21 (WAF1\/CIP1) gene and its impact on expression and role of polymorphism in the risk of breast cancer. Mol. Cell. Biochem. 382, 19\u201326. https:\/\/doi.org\/10.1007\/s11010-013-1696-5 (2013).","journal-title":"Mol. Cell. Biochem."},{"key":"31087_CR92","first-page":"4391","volume":"26","author":"Y Ito","year":"2006","unstructured":"Ito, Y. et al. Decreased expression of tumor protein p53-induced nuclear protein 1 (TP53INP1) in breast carcinoma. Anticancer Res. 26, 4391\u20134395 (2006).","journal-title":"Anticancer Res."},{"key":"31087_CR93","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s10495-023-01934-1","volume":"29","author":"F Li","year":"2024","unstructured":"Li, F. et al. A self-amplifying loop of TP53INP1 and P53 drives oxidative stress-induced apoptosis of bone marrow mesenchymal stem cells. Apoptosis 29, 882\u2013897. https:\/\/doi.org\/10.1007\/s10495-023-01934-1 (2024).","journal-title":"Apoptosis"},{"key":"31087_CR94","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fgene.2013.00080","volume":"4","author":"J Shahbazi","year":"2013","unstructured":"Shahbazi, J., Lock, R. & Liu, T. Tumor protein 53-Induced nuclear protein 1 enhances p53 function and represses tumorigenesis. Front. Genet. 4, 80. https:\/\/doi.org\/10.3389\/fgene.2013.00080 (2013).","journal-title":"Front. Genet."},{"key":"31087_CR95","doi-asserted-by":"publisher","first-page":"18440","DOI":"10.18632\/oncotarget.7825","volume":"7","author":"R Xu","year":"2016","unstructured":"Xu, R. et al. Alkaline ceramidase 2 and its bioactive product sphingosine are novel regulators of the DNA damage response. Oncotarget 7, 18440\u201318457. https:\/\/doi.org\/10.18632\/oncotarget.7825 (2016).","journal-title":"Oncotarget"},{"key":"31087_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124481","author":"M Francis","year":"2020","unstructured":"Francis, M., Abou Daher, A., Azzam, P., Mroueh, M. & Zeidan, Y. H. Modulation of DNA damage response by sphingolipid signaling: an interplay that shapes cell fate. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21124481 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"31087_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/cells14080598","author":"F AlMaazmi","year":"2025","unstructured":"AlMaazmi, F., Bou Malhab, I., J, L., ElDohaji, L. & Saber-Ayad, M. Deciphering the controversial role of TP53 inducible glycolysis and apoptosis regulator (TIGAR) in cancer metabolism as a potential therapeutic strategy. Cells https:\/\/doi.org\/10.3390\/cells14080598 (2025).","journal-title":"Cells"},{"key":"31087_CR98","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/bjc.2012.260","volume":"107","author":"E Madan","year":"2012","unstructured":"Madan, E. et al. TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex. Br. J. Cancer. 107, 516\u2013526. https:\/\/doi.org\/10.1038\/bjc.2012.260 (2012).","journal-title":"Br. J. Cancer"},{"key":"31087_CR99","doi-asserted-by":"publisher","first-page":"109956","DOI":"10.1016\/j.biopha.2020.109956","volume":"125","author":"W Deng","year":"2020","unstructured":"Deng, W. et al. The role of PPM1D in cancer and advances in studies of its inhibitors. Biomed. Pharmacother. 125, 109956. https:\/\/doi.org\/10.1016\/j.biopha.2020.109956 (2020).","journal-title":"Biomed. Pharmacother"},{"key":"31087_CR100","doi-asserted-by":"publisher","first-page":"13855","DOI":"10.1007\/s13277-016-5133-8","volume":"37","author":"RA Canevari","year":"2016","unstructured":"Canevari, R. A. et al. Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma. Tumour Biol. 37, 13855\u201313870. https:\/\/doi.org\/10.1007\/s13277-016-5133-8 (2016).","journal-title":"Tumour Biol."},{"key":"31087_CR101","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/ng894","volume":"31","author":"DV Bulavin","year":"2002","unstructured":"Bulavin, D. V. et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet. 31, 210\u2013215. https:\/\/doi.org\/10.1038\/ng894 (2002).","journal-title":"Nat. Genet."},{"key":"31087_CR102","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10549-005-9017-7","volume":"95","author":"J Rauta","year":"2006","unstructured":"Rauta, J. et al. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res. Treat. 95, 257\u2013263. https:\/\/doi.org\/10.1007\/s10549-005-9017-7 (2006).","journal-title":"Breast Cancer Res. Treat."},{"key":"31087_CR103","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/modpathol.2010.121","volume":"23","author":"MB Lambros","year":"2010","unstructured":"Lambros, M. B. et al. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod. Pathol. 23, 1334\u20131345. https:\/\/doi.org\/10.1038\/modpathol.2010.121 (2010).","journal-title":"Mod. Pathol."},{"key":"31087_CR104","doi-asserted-by":"publisher","first-page":"555","DOI":"10.4161\/cbt.8.6.7742","volume":"8","author":"W Kong","year":"2009","unstructured":"Kong, W., Jiang, X. & Mercer, W. E. Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax. Cancer Biol. Ther. 8, 555\u2013563. https:\/\/doi.org\/10.4161\/cbt.8.6.7742 (2009).","journal-title":"Cancer Biol. Ther."},{"key":"31087_CR105","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3892\/ol.2017.6361","volume":"14","author":"ZS Xia","year":"2017","unstructured":"Xia, Z. S. et al. Wip1 gene Silencing enhances the chemosensitivity of human colon cancer cells. Oncol. Lett. 14, 1875\u20131883. https:\/\/doi.org\/10.3892\/ol.2017.6361 (2017).","journal-title":"Oncol. Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31087-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31087-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31087-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T18:04:29Z","timestamp":1768327469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31087-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31087"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31087-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1397"}}